Skip to main content
Erschienen in: Drugs & Aging 3/2005

01.03.2005 | Original Research Article

Atypical Antipsychotics for Nursing Home Patients

A Retrospective Chart Review

verfasst von: Dr I. Barton Frenchman

Erschienen in: Drugs & Aging | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

To compare the efficacy and safety of risperidone and olanzapine in the treatment of psychotic symptoms and behavioural disturbances in institutionalised patients with dementia and other psychiatric disorders.

Methods

We conducted a retrospective chart review of nursing home patients with psychiatric disorders or dementia in 65 long-term care facilities in New Jersey and Pennsylvania who had received treatment with risperidone or olanzapine. We determined the efficacy of the two antipsychotics for the treatment of psychotic symptoms or behavioural disorders in patients with dementia, the incidence of falls in ambulatory patients, and the incidence of adverse events in the total sample of patients.

Results

A total of 289 long-term care patients were included in the analysis. Diagnoses included dementia in 59%, schizophrenia in 20%, bipolar disorder in 8%, schizoaffective disorder in 6% and other diagnoses in 10%. The mean ages were 77 years in patients receiving risperidone and 81 years in patients receiving olanzapine. Risperidone was received by 141 patients and olanzapine by 148 patients. In the 171 patients with dementia, significantly greater improvements in psychotic symptoms and behavioural disturbances were seen in patients receiving risperidone compared with those receiving olanzapine (p < 0.05). In the 222 ambulatory patients, ≥1 fall was recorded in 19% of patients receiving risperidone and in 38% of patients receiving olanzapine (p = 0.001). The fall rate per month was 0.06 in risperidone recipients and 0.17 in olanzapine recipients (p < 0.001). Adverse events were reported in 6% (9/141) of risperidone-treated patients compared with 34% (42/110) of olanzapine-treated patients (p < 0.001). Adverse events seen only in the olanzapine group were constipation, dry mouth, dysphasia, sedation and dizziness.

Conclusion

The results of this review indicate that risperidone was more efficacious and better tolerated than olanzapine in the treatment of nursing home patients with psychotic symptoms and behavioural disturbances.
Literatur
1.
Zurück zum Zitat O’Connor DW. Epidemiology of behavioral and psychological symptoms of dementia. Int Psychogeriatr 2000; 12Suppl. 1: 41–6CrossRef O’Connor DW. Epidemiology of behavioral and psychological symptoms of dementia. Int Psychogeriatr 2000; 12Suppl. 1: 41–6CrossRef
2.
Zurück zum Zitat De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999 Sep 22; 53: 946–55PubMedCrossRef De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999 Sep 22; 53: 946–55PubMedCrossRef
3.
Zurück zum Zitat Frenchman IB, Prince T. Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr 1997; 9: 431–5PubMedCrossRef Frenchman IB, Prince T. Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr 1997; 9: 431–5PubMedCrossRef
4.
Zurück zum Zitat Jeste DV, Barak Y, Madhusoodanan S, et al. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003; 11: 638–47PubMed Jeste DV, Barak Y, Madhusoodanan S, et al. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003; 11: 638–47PubMed
5.
Zurück zum Zitat Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60: 107–15PubMedCrossRef Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60: 107–15PubMedCrossRef
6.
Zurück zum Zitat Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000; 57: 968–76PubMedCrossRef Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000; 57: 968–76PubMedCrossRef
7.
Zurück zum Zitat Zaudig M. A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia. Drug Saf 2000; 23: 183–95PubMedCrossRef Zaudig M. A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia. Drug Saf 2000; 23: 183–95PubMedCrossRef
8.
Zurück zum Zitat Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17: 363–84PubMedCrossRef Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17: 363–84PubMedCrossRef
9.
Zurück zum Zitat Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150–5PubMedCrossRef Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150–5PubMedCrossRef
10.
Zurück zum Zitat Bhana N, Spencer CM. Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs Aging 2000; 16: 451–71PubMedCrossRef Bhana N, Spencer CM. Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs Aging 2000; 16: 451–71PubMedCrossRef
11.
Zurück zum Zitat DeVane CL, Mintzer J. Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update. Psychopharmacol Bull 2003; 37: 116–32PubMed DeVane CL, Mintzer J. Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update. Psychopharmacol Bull 2003; 37: 116–32PubMed
12.
Zurück zum Zitat Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134–43PubMedCrossRef Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134–43PubMedCrossRef
13.
Zurück zum Zitat Martin H, Slyk MP, Deymann S, et al. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia. J Am Med Dir Assoc 2003; 4: 183–8PubMedCrossRef Martin H, Slyk MP, Deymann S, et al. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia. J Am Med Dir Assoc 2003; 4: 183–8PubMedCrossRef
14.
Zurück zum Zitat Katz I, Schneider L, Kozma C, et al. Risk of falls in dementia patients: analysis of a randomized, double-blind risperidone trial. Poster presented at the American Association for Geriatric Psychiatry Annual Meeting; 2002 Mar 1–4; Waikiki, Hawaii Katz I, Schneider L, Kozma C, et al. Risk of falls in dementia patients: analysis of a randomized, double-blind risperidone trial. Poster presented at the American Association for Geriatric Psychiatry Annual Meeting; 2002 Mar 1–4; Waikiki, Hawaii
15.
Zurück zum Zitat De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2004; 19: 115–26PubMedCrossRef De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2004; 19: 115–26PubMedCrossRef
Metadaten
Titel
Atypical Antipsychotics for Nursing Home Patients
A Retrospective Chart Review
verfasst von
Dr I. Barton Frenchman
Publikationsdatum
01.03.2005
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 3/2005
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200522030-00006

Weitere Artikel der Ausgabe 3/2005

Drugs & Aging 3/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.